| Dr Shaheen Ibrahim Umar, MD | |
|
12606 E Mission Ave, Spokane Valley, WA 99216-3421 | |
| (509) 924-6650 | |
| (094) 735-4905 |
| Full Name | Dr Shaheen Ibrahim Umar |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 21 Years |
| Location | 12606 E Mission Ave, Spokane Valley, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942466156 | NPI | - | NPPES |
| 0429128 | Other | WA | L&I-SOUTH SOUND RADIOLOGY |
| 2166230 | Other | WA | L&I-VANCOUVER RADIOLOGY |
| 0429123 | Other | WA | L&I-RADIA KING CTY |
| 0429127 | Other | WA | L&I-EVERGREEN RADIA |
| 2166230 | Medicaid | WA | |
| 2166230 | Other | WA | L&I-SEATTLE RADIOLOGY |
| 0429122 | Other | WA | L&I-RADIA REST OF WA |
| 0429124 | Other | WA | L&I-SWEDISH RADIA EDMONDS |
| Facility Name | Location | Facility Type |
|---|---|---|
| Overlake Hospital Medical Center | Bellevue, WA | Hospital |
| Swedish Medical Center / Cherry Hill | Seattle, WA | Hospital |
| Providence St Peter Hospital | Olympia, WA | Hospital |
| Asante Rogue Regional Medical Center | Medford, OR | Hospital |
| Providence Regional Medical Center Everett | Everett, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medford Radiological Group Pc | 2062303324 | 78 |
| Tower Imaging Medical Associates Inc | 2163608688 | 42 |
| Central Washington Health Services Association | 4880504596 | 645 |
| Radia Inc P S | 9931012812 | 254 |
| Swedish Health Services | 3173433067 | 103 |
| Radiology Associates Pa | 7517953912 | 89 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
For years, Richard Manning knew what he needed to cope with his physical pain, rage and PTSD — much of which he traced to a career-ending knee injury he suffered while on a domestic security detail with the Marines.
Normal-weight women who carry out lots of vigorous exercise are approximately 30% less likely to develop breast cancer than those who don't exercise vigorously.
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
In the general population, African Americans die at earlier ages than whites, but among patients on dialysis, African Americans live longer than whites. A new study helps explain this paradox and could help prolong the lives of all patients on dialysis.
› Verified 7 days ago
| Entity Name | Ssm Cardinal Glennon Children's Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174577670 PECOS PAC ID: 7012828163 Enrollment ID: O20031231000604 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
For years, Richard Manning knew what he needed to cope with his physical pain, rage and PTSD — much of which he traced to a career-ending knee injury he suffered while on a domestic security detail with the Marines.
Normal-weight women who carry out lots of vigorous exercise are approximately 30% less likely to develop breast cancer than those who don't exercise vigorously.
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
In the general population, African Americans die at earlier ages than whites, but among patients on dialysis, African Americans live longer than whites. A new study helps explain this paradox and could help prolong the lives of all patients on dialysis.
› Verified 7 days ago
| Entity Name | Valley Imaging Consultants Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215987045 PECOS PAC ID: 6800882374 Enrollment ID: O20180302002293 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
For years, Richard Manning knew what he needed to cope with his physical pain, rage and PTSD — much of which he traced to a career-ending knee injury he suffered while on a domestic security detail with the Marines.
Normal-weight women who carry out lots of vigorous exercise are approximately 30% less likely to develop breast cancer than those who don't exercise vigorously.
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
In the general population, African Americans die at earlier ages than whites, but among patients on dialysis, African Americans live longer than whites. A new study helps explain this paradox and could help prolong the lives of all patients on dialysis.
› Verified 7 days ago
| Entity Name | Radia Inc P S |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932196607 PECOS PAC ID: 9931012812 Enrollment ID: O20191007001242 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
For years, Richard Manning knew what he needed to cope with his physical pain, rage and PTSD — much of which he traced to a career-ending knee injury he suffered while on a domestic security detail with the Marines.
Normal-weight women who carry out lots of vigorous exercise are approximately 30% less likely to develop breast cancer than those who don't exercise vigorously.
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
In the general population, African Americans die at earlier ages than whites, but among patients on dialysis, African Americans live longer than whites. A new study helps explain this paradox and could help prolong the lives of all patients on dialysis.
› Verified 7 days ago
| Entity Name | Medford Radiological Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407938111 PECOS PAC ID: 2062303324 Enrollment ID: O20220126002278 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
For years, Richard Manning knew what he needed to cope with his physical pain, rage and PTSD — much of which he traced to a career-ending knee injury he suffered while on a domestic security detail with the Marines.
Normal-weight women who carry out lots of vigorous exercise are approximately 30% less likely to develop breast cancer than those who don't exercise vigorously.
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
In the general population, African Americans die at earlier ages than whites, but among patients on dialysis, African Americans live longer than whites. A new study helps explain this paradox and could help prolong the lives of all patients on dialysis.
› Verified 7 days ago
| Entity Name | Wenatchee Valley Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669719688 PECOS PAC ID: 9537309869 Enrollment ID: O20220822001823 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
For years, Richard Manning knew what he needed to cope with his physical pain, rage and PTSD — much of which he traced to a career-ending knee injury he suffered while on a domestic security detail with the Marines.
Normal-weight women who carry out lots of vigorous exercise are approximately 30% less likely to develop breast cancer than those who don't exercise vigorously.
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
In the general population, African Americans die at earlier ages than whites, but among patients on dialysis, African Americans live longer than whites. A new study helps explain this paradox and could help prolong the lives of all patients on dialysis.
› Verified 7 days ago
| Entity Name | Professional Imaging Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447477161 PECOS PAC ID: 2062440126 Enrollment ID: O20221104002229 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
For years, Richard Manning knew what he needed to cope with his physical pain, rage and PTSD — much of which he traced to a career-ending knee injury he suffered while on a domestic security detail with the Marines.
Normal-weight women who carry out lots of vigorous exercise are approximately 30% less likely to develop breast cancer than those who don't exercise vigorously.
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
In the general population, African Americans die at earlier ages than whites, but among patients on dialysis, African Americans live longer than whites. A new study helps explain this paradox and could help prolong the lives of all patients on dialysis.
› Verified 7 days ago
| Entity Name | Tower Imaging Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023315074 PECOS PAC ID: 2163608688 Enrollment ID: O20221222000947 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
For years, Richard Manning knew what he needed to cope with his physical pain, rage and PTSD — much of which he traced to a career-ending knee injury he suffered while on a domestic security detail with the Marines.
Normal-weight women who carry out lots of vigorous exercise are approximately 30% less likely to develop breast cancer than those who don't exercise vigorously.
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
In the general population, African Americans die at earlier ages than whites, but among patients on dialysis, African Americans live longer than whites. A new study helps explain this paradox and could help prolong the lives of all patients on dialysis.
› Verified 7 days ago
| Entity Name | Central Washington Health Services Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881642239 PECOS PAC ID: 4880504596 Enrollment ID: O20230302001949 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
For years, Richard Manning knew what he needed to cope with his physical pain, rage and PTSD — much of which he traced to a career-ending knee injury he suffered while on a domestic security detail with the Marines.
Normal-weight women who carry out lots of vigorous exercise are approximately 30% less likely to develop breast cancer than those who don't exercise vigorously.
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
In the general population, African Americans die at earlier ages than whites, but among patients on dialysis, African Americans live longer than whites. A new study helps explain this paradox and could help prolong the lives of all patients on dialysis.
› Verified 7 days ago
| Entity Name | Radia Oregon Radiology Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073385423 PECOS PAC ID: 2961852637 Enrollment ID: O20240302000061 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
For years, Richard Manning knew what he needed to cope with his physical pain, rage and PTSD — much of which he traced to a career-ending knee injury he suffered while on a domestic security detail with the Marines.
Normal-weight women who carry out lots of vigorous exercise are approximately 30% less likely to develop breast cancer than those who don't exercise vigorously.
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
In the general population, African Americans die at earlier ages than whites, but among patients on dialysis, African Americans live longer than whites. A new study helps explain this paradox and could help prolong the lives of all patients on dialysis.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shaheen Ibrahim Umar, MD 19020 33rd Ave W Ste 210, Lynnwood, WA 98036-4748 Ph: (425) 563-1500 | Dr Shaheen Ibrahim Umar, MD 12606 E Mission Ave, Spokane Valley, WA 99216-3421 Ph: (509) 924-6650 |
News Archive
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
For years, Richard Manning knew what he needed to cope with his physical pain, rage and PTSD — much of which he traced to a career-ending knee injury he suffered while on a domestic security detail with the Marines.
Normal-weight women who carry out lots of vigorous exercise are approximately 30% less likely to develop breast cancer than those who don't exercise vigorously.
Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.
In the general population, African Americans die at earlier ages than whites, but among patients on dialysis, African Americans live longer than whites. A new study helps explain this paradox and could help prolong the lives of all patients on dialysis.
› Verified 7 days ago
Dr. Lisa P Maestas, D.O. Radiology Medicare: Medicare Enrolled Practice Location: 12410 E Sinto Ave Ste B, Spokane Valley, WA 99216 Phone: 509-838-2531 Fax: 509-755-6580 | |
Christopher Melvin Lee, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1204 N Vercler Rd, Ste201, Spokane Valley, WA 99216 Phone: 509-228-1000 Fax: 509-252-9300 | |
Dr. Robert H. Goebel, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 12410 E Sinto Ave Ste B, Suite A100, Spokane Valley, WA 99216 Phone: 509-838-2531 Fax: 509-755-6580 | |
Michael F Kos, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 13424 E Mission Ave # A, Spokane Valley, WA 99216 Phone: 509-321-4980 Fax: 530-576-0364 | |
Dr. Karie-lynn Janet Kelly, M.D.. F.R.C.P.C. Radiology Medicare: Accepting Medicare Assignments Practice Location: 13424 E Mission Ave, Spokane Valley, WA 99216 Phone: 509-462-2273 | |
John A. Shaw, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 12410 E Sinto Ave Ste B, Spokane Valley, WA 99216 Phone: 509-838-2531 | |
David E Davenport, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1204 N Vercler Rd, Ste 101, Spokane Valley, WA 99216 Phone: 509-228-1000 Fax: 509-252-9300 |